Develops oral insulin capsules for type 2 diabetes patients.
Dec 2025Revenue $2.00M/yrExpenses $17.1M/yr
No trendCash runway ≈ 3.1 years from Jun 2026
Figures by year
When will Oramed Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $2.00M and expenses $17.1M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.00M | $17.1M | −$15.1M |
| Dec 2023 | $1.34M | $17.1M | −$15.8M |
| Dec 2022 | $2.70M | $43.3M | −$40.6M |
| Aug 2021 | $2.70M | $26.9M | −$24.2M |
| Aug 2020 | $2.71M | $14.5M | −$11.8M |
| Aug 2019 | $2.70M | $17.3M | −$14.6M |
| Aug 2018 | $2.45M | $16.0M | −$13.5M |
| Aug 2017 | $2.46M | $13.2M | −$10.8M |
| Aug 2016 | $641K | $10.7M | −$10.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.